|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ADIPOR1 |
Gene summary for ADIPOR1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ADIPOR1 | Gene ID | 51094 |
| Gene name | adiponectin receptor 1 | |
| Gene Alias | ACDCR1 | |
| Cytomap | 1q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0001558 | UniProtAcc | Q96A54 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51094 | ADIPOR1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.96e-02 | 2.24e-01 | -0.1808 |
| 51094 | ADIPOR1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 7.27e-03 | 2.51e-01 | -0.0811 |
| 51094 | ADIPOR1 | HTA11_78_2000001011 | Human | Colorectum | AD | 8.77e-08 | 4.21e-01 | -0.1088 |
| 51094 | ADIPOR1 | HTA11_347_2000001011 | Human | Colorectum | AD | 6.17e-09 | 2.96e-01 | -0.1954 |
| 51094 | ADIPOR1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 4.47e-06 | 3.15e-01 | -0.059 |
| 51094 | ADIPOR1 | HTA11_2992_2000001011 | Human | Colorectum | SER | 3.97e-02 | 3.22e-01 | -0.1706 |
| 51094 | ADIPOR1 | HTA11_866_3004761011 | Human | Colorectum | AD | 3.07e-06 | 1.82e-01 | 0.096 |
| 51094 | ADIPOR1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.25e-02 | 1.99e-01 | 0.0674 |
| 51094 | ADIPOR1 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.02e-04 | 3.49e-01 | 0.0588 |
| 51094 | ADIPOR1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.47e-08 | 3.17e-01 | 0.294 |
| 51094 | ADIPOR1 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 2.88e-02 | 5.32e-01 | 0.3487 |
| 51094 | ADIPOR1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 3.54e-09 | 4.72e-01 | 0.281 |
| 51094 | ADIPOR1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.06e-12 | 4.52e-01 | 0.3859 |
| 51094 | ADIPOR1 | LZE3D | Human | Esophagus | HGIN | 4.56e-07 | 3.14e-01 | 0.0668 |
| 51094 | ADIPOR1 | LZE4T | Human | Esophagus | ESCC | 1.28e-06 | 4.48e-01 | 0.0811 |
| 51094 | ADIPOR1 | LZE7T | Human | Esophagus | ESCC | 1.95e-05 | 8.58e-01 | 0.0667 |
| 51094 | ADIPOR1 | LZE20T | Human | Esophagus | ESCC | 9.37e-05 | 3.56e-01 | 0.0662 |
| 51094 | ADIPOR1 | LZE22T | Human | Esophagus | ESCC | 7.21e-03 | 1.05e+00 | 0.068 |
| 51094 | ADIPOR1 | LZE24T | Human | Esophagus | ESCC | 1.70e-18 | 1.04e+00 | 0.0596 |
| 51094 | ADIPOR1 | LZE21T | Human | Esophagus | ESCC | 1.41e-03 | 1.33e-01 | 0.0655 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000600614 | Oral cavity | LP | glucose metabolic process | 64/4623 | 196/18723 | 7.09e-03 | 3.98e-02 | 64 |
| GO:001604910 | Prostate | BPH | cell growth | 139/3107 | 482/18723 | 7.53e-12 | 5.90e-10 | 139 |
| GO:190165310 | Prostate | BPH | cellular response to peptide | 104/3107 | 359/18723 | 2.51e-09 | 1.00e-07 | 104 |
| GO:000155810 | Prostate | BPH | regulation of cell growth | 116/3107 | 414/18723 | 2.66e-09 | 1.05e-07 | 116 |
| GO:009013216 | Prostate | BPH | epithelium migration | 104/3107 | 360/18723 | 2.96e-09 | 1.15e-07 | 104 |
| GO:009013016 | Prostate | BPH | tissue migration | 105/3107 | 365/18723 | 3.21e-09 | 1.24e-07 | 105 |
| GO:001063116 | Prostate | BPH | epithelial cell migration | 103/3107 | 357/18723 | 3.80e-09 | 1.44e-07 | 103 |
| GO:000166717 | Prostate | BPH | ameboidal-type cell migration | 128/3107 | 475/18723 | 5.69e-09 | 2.05e-07 | 128 |
| GO:001063216 | Prostate | BPH | regulation of epithelial cell migration | 87/3107 | 292/18723 | 1.18e-08 | 3.87e-07 | 87 |
| GO:004343417 | Prostate | BPH | response to peptide hormone | 109/3107 | 414/18723 | 2.73e-07 | 5.91e-06 | 109 |
| GO:00713759 | Prostate | BPH | cellular response to peptide hormone stimulus | 82/3107 | 290/18723 | 3.65e-07 | 7.65e-06 | 82 |
| GO:003286910 | Prostate | BPH | cellular response to insulin stimulus | 61/3107 | 203/18723 | 1.26e-06 | 2.20e-05 | 61 |
| GO:003286810 | Prostate | BPH | response to insulin | 73/3107 | 264/18723 | 3.80e-06 | 5.83e-05 | 73 |
| GO:00512715 | Prostate | BPH | negative regulation of cellular component movement | 94/3107 | 367/18723 | 6.18e-06 | 9.00e-05 | 94 |
| GO:00459265 | Prostate | BPH | negative regulation of growth | 68/3107 | 249/18723 | 1.26e-05 | 1.69e-04 | 68 |
| GO:20001465 | Prostate | BPH | negative regulation of cell motility | 91/3107 | 359/18723 | 1.34e-05 | 1.76e-04 | 91 |
| GO:00018376 | Prostate | BPH | epithelial to mesenchymal transition | 47/3107 | 157/18723 | 2.21e-05 | 2.67e-04 | 47 |
| GO:00400135 | Prostate | BPH | negative regulation of locomotion | 96/3107 | 391/18723 | 3.11e-05 | 3.54e-04 | 96 |
| GO:00303365 | Prostate | BPH | negative regulation of cell migration | 86/3107 | 344/18723 | 3.93e-05 | 4.25e-04 | 86 |
| GO:00097559 | Prostate | BPH | hormone-mediated signaling pathway | 53/3107 | 190/18723 | 5.92e-05 | 5.97e-04 | 53 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04932 | Colorectum | AD | Non-alcoholic fatty liver disease | 90/2092 | 155/8465 | 4.83e-19 | 1.80e-17 | 1.15e-17 | 90 |
| hsa04152 | Colorectum | AD | AMPK signaling pathway | 47/2092 | 121/8465 | 3.74e-04 | 2.82e-03 | 1.80e-03 | 47 |
| hsa04211 | Colorectum | AD | Longevity regulating pathway | 33/2092 | 89/8465 | 6.15e-03 | 2.68e-02 | 1.71e-02 | 33 |
| hsa049321 | Colorectum | AD | Non-alcoholic fatty liver disease | 90/2092 | 155/8465 | 4.83e-19 | 1.80e-17 | 1.15e-17 | 90 |
| hsa041521 | Colorectum | AD | AMPK signaling pathway | 47/2092 | 121/8465 | 3.74e-04 | 2.82e-03 | 1.80e-03 | 47 |
| hsa042111 | Colorectum | AD | Longevity regulating pathway | 33/2092 | 89/8465 | 6.15e-03 | 2.68e-02 | 1.71e-02 | 33 |
| hsa042112 | Colorectum | MSS | Longevity regulating pathway | 33/1875 | 89/8465 | 9.33e-04 | 5.58e-03 | 3.42e-03 | 33 |
| hsa041522 | Colorectum | MSS | AMPK signaling pathway | 41/1875 | 121/8465 | 1.91e-03 | 9.83e-03 | 6.03e-03 | 41 |
| hsa042113 | Colorectum | MSS | Longevity regulating pathway | 33/1875 | 89/8465 | 9.33e-04 | 5.58e-03 | 3.42e-03 | 33 |
| hsa041523 | Colorectum | MSS | AMPK signaling pathway | 41/1875 | 121/8465 | 1.91e-03 | 9.83e-03 | 6.03e-03 | 41 |
| hsa04932210 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
| hsa0415210 | Esophagus | ESCC | AMPK signaling pathway | 80/4205 | 121/8465 | 1.73e-04 | 6.67e-04 | 3.42e-04 | 80 |
| hsa0421114 | Esophagus | ESCC | Longevity regulating pathway | 58/4205 | 89/8465 | 2.19e-03 | 6.16e-03 | 3.16e-03 | 58 |
| hsa0493238 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
| hsa0415213 | Esophagus | ESCC | AMPK signaling pathway | 80/4205 | 121/8465 | 1.73e-04 | 6.67e-04 | 3.42e-04 | 80 |
| hsa0421115 | Esophagus | ESCC | Longevity regulating pathway | 58/4205 | 89/8465 | 2.19e-03 | 6.16e-03 | 3.16e-03 | 58 |
| hsa0493222 | Liver | Cirrhotic | Non-alcoholic fatty liver disease | 106/2530 | 155/8465 | 2.16e-23 | 2.40e-21 | 1.48e-21 | 106 |
| hsa04936 | Liver | Cirrhotic | Alcoholic liver disease | 60/2530 | 142/8465 | 1.07e-03 | 5.85e-03 | 3.61e-03 | 60 |
| hsa0415221 | Liver | Cirrhotic | AMPK signaling pathway | 49/2530 | 121/8465 | 7.90e-03 | 2.74e-02 | 1.69e-02 | 49 |
| hsa042118 | Liver | Cirrhotic | Longevity regulating pathway | 37/2530 | 89/8465 | 1.22e-02 | 3.89e-02 | 2.40e-02 | 37 |
| Page: 1 2 3 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ADIPOR1 | SNV | Missense_Mutation | novel | c.824N>A | p.Gly275Asp | p.G275D | Q96A54 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| ADIPOR1 | SNV | Missense_Mutation | c.167T>C | p.Val56Ala | p.V56A | Q96A54 | protein_coding | tolerated(0.89) | benign(0) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
| ADIPOR1 | SNV | Missense_Mutation | novel | c.559N>C | p.Ser187Pro | p.S187P | Q96A54 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A1OH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | CR |
| ADIPOR1 | SNV | Missense_Mutation | novel | c.648T>G | p.Ile216Met | p.I216M | Q96A54 | protein_coding | deleterious(0.04) | possibly_damaging(0.706) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| ADIPOR1 | SNV | Missense_Mutation | c.296T>C | p.Val99Ala | p.V99A | Q96A54 | protein_coding | tolerated(0.52) | benign(0) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ADIPOR1 | SNV | Missense_Mutation | novel | c.605G>A | p.Arg202Gln | p.R202Q | Q96A54 | protein_coding | tolerated(0.09) | benign(0.025) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ADIPOR1 | SNV | Missense_Mutation | novel | c.677N>G | p.Tyr226Cys | p.Y226C | Q96A54 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ADIPOR1 | SNV | Missense_Mutation | novel | c.493N>T | p.Ala165Ser | p.A165S | Q96A54 | protein_coding | tolerated(0.19) | benign(0.199) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| ADIPOR1 | SNV | Missense_Mutation | novel | c.226G>A | p.Ala76Thr | p.A76T | Q96A54 | protein_coding | tolerated(0.08) | possibly_damaging(0.701) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| ADIPOR1 | SNV | Missense_Mutation | novel | c.797C>T | p.Thr266Ile | p.T266I | Q96A54 | protein_coding | tolerated(0.38) | benign(0.017) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |